PMV Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of PMV Pharmaceuticals generated cash of -$55,657,000, which is more than the previous year. Cash used in financing activities reached the amount of $35,577,000 last year. Net change in cash is therefore -$70,591,000.
Cash Flow
| 2018 | -15.17M | 21.69M | 0 |
|---|---|---|---|
| 2019 | -22.06M | 3.23M | 61.80M |
| 2020 | -32.73M | 27.91M | 292.97M |
| 2021 | -46.57M | -143.58M | 2.02M |
| 2022 | -63.76M | -1.36M | 958K |
| 2023 | -55.65M | -50.54M | 35.57M |
PMVP Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 109.11M | 173.28M | 361.42M | 73.27M | 30.30M | 23.79M |
Operating activities | ||||||
Net income | -68.96M | -73.31M | -57.84M | -34.44M | -25.35M | -17.53M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 1.25M | 315K | 307K | 318K | 388K | 338K |
Stock-based compensation expense | 12.37M | 10.19M | 5.34M | 1.93M | 908K | 0 |
| Deferred income tax benefit | 12.37M | 10.19M | 5.34M | 1.93M | 908K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 235K | -389K | 191K | -1.23M | 1.79M | 267K |
Cash generated by operating activities | -55.65M | -63.76M | -46.57M | -32.73M | -22.06M | -15.17M |
Investing activities | ||||||
Purchases Of Investments | -220.53M | -229.19M | -256.84M | -14.51M | -43.45M | -48.67M |
Investments In Property Plant And Equipment | -962K | -7.98M | -1.34M | -148K | -109K | -452K |
Acquisitions Net | 0 | -6.61K | 2.74M | 148K | -3.34K | 0 |
Cash generated by investing activities | -50.54M | -1.36M | -143.58M | 27.91M | 3.23M | 21.69M |
Financing activities | ||||||
Common Stock Issued | 35.12M | 958K | 2.02M | 292.97M | 61.80M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 35.57M | 958K | 2.02M | 292.97M | 61.80M | 0 |
Net Change In Cash | -70.59M | -64.17M | -188.13M | 288.14M | 42.97M | 6.51M |
Cash at end of period | 38.52M | 109.11M | 173.28M | 361.42M | 73.27M | 30.30M |
| Data source | Data source | Data source | Data source |